Med24
peptide-development 14. 10. 2026 • 2 min read • Diabetes, obesity & metabolism

Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity

Aims Glucagon-like peptide-1 (GLP-1) receptor agonist-based medicines are highly effective treatments for overweight and obesity, but population-scale real-world evidence remains limited, particularly in self-funded settings where treatment choice may be influenced by relative price. We aimed to characterise provider...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

A study examined treatment patterns and weight outcomes for adults with overweight or obesity using glucagon-like peptide-1 (GLP-1) receptor agonists through a UK telehealth provider. The research analyzed data from 1,033,522 adults initiating either semaglutide or tirzepatide between May 1, 2024, and January 1, 2026.

Treatment Patterns and Patient Demographics

Ninety-two percent of those initiating treatment chose tirzepatide, while nine percent chose semaglutide. Provider reach was higher among women compared to men. Following a projected increase in the tirzepatide list price, there was a notable shift in treatment choices. Semaglutide initiation increased by 31.15 percentage points relative to the expected trend, while tirzepatide-to-semaglutide switching increased by 9.26 percentage points. Sensitivity analyses confirmed these changes occurred prior to the September 2025 price adjustment.

Sponsored content

Clinical Outcomes

At twelve months, estimated weight loss was 19.93% with tirzepatide and 16.40% with semaglutide. The study involved 30,763 patients on tirzepatide and 979 patients on semaglutide. The research highlights the significant impact of treatment costs on patient selection and treatment pathways within a real-world setting. The study’s findings suggest that changes in relative pricing can substantially alter treatment patterns and, consequently, influence weight loss outcomes among individuals receiving GLP-1 receptor agonist therapy.

Original Scientific Source
Diabetes, obesity & metabolism
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
peptide-development

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

1. 12. 2026 Read article →
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
peptide-development

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

10. 11. 2026 Read article →
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome
peptide-development

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

23. 10. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Advertisement